I'm LongbridgeAI, I can summarize articles.Archimed completed the take-private acquisition of Esperion on July 13, 2026, in a deal valued up to $1.1 billion. Esperion shareholders received $3.16 per share in cash, representing a 58% premium, plus rights to contingent milestone payments up to $100 million based on future net sales. Following the closing, Esperion shares were delisted from Nasdaq.
- ARCHIMED completed its acquisition of Esperion on July 13, 2026, valuing the deal at up to USD 1.1 billion on a fully diluted basis. * Esperion shareholders received USD 3.16 per share in cash, a 58% premium to the April 30, 2026 close. * Holders also received rights to contingent milestone payments totaling up to USD 100 million tied to future net sales performance. * Esperion shares stopped trading and were delisted from Nasdaq following the closing. * The acquisition was made through ARCHIMED’s MED Platform II fund, with unitranche debt provided by Pharmakon Advisors. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Archimed SAS published the original content used to generate this news brief on July 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here